Wilkes NSG 533 Advanced Pharmacology Exam 4 Prep
Document | 2026/2027 Edition | 150 Verified Questions - 115
Questions with Answers
Wilkes NSG 533 Advanced Pharmacology Exam 4 2026-115 QUESTIONS AND ANSWERS ALREADY GRADED
A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation resource for Wilkes University's NSG 533 Advanced
Pharmacology course (Exam 4) contains 150 verified practice questions and answers, meticulously
aligned with the 2026-2027 academic year's curriculum and the latest clinical practice guidelines. Each
question is designed to test advanced pharmacotherapeutic concepts, including drug mechanisms,
adverse effects, drug interactions, and patient-specific considerations. The document serves as an
essential tool for graduate nursing students seeking to excel in their pharmacology coursework and
prepare for board examinations.
Key Features:
Pharmacokinetics and pharmacodynamics of major drug classes
Clinical application of antimicrobial, cardiovascular, and psychotropic agents
Evidence-based prescribing for special populations (geriatric, pediatric, pregnant)
Drug-drug interactions and adverse effect management
Patient education and monitoring parameters for high-alert medications
Case-based scenarios to enhance critical thinking and clinical reasoning
Updates for 2026:
- Updated to reflect the latest FDA approvals and safety alerts as of 2026
- Revised to incorporate current evidence-based guidelines from major medical societies
- Expanded rationales to include recent clinical trial findings and pharmacogenomic considerations
- Enhanced coverage of opioid stewardship and controlled substance prescribing regulations
- Aligned with the 2026-2027 AACN Essentials and advanced pharmacology competencies
Abstract:
This exam preparation document for Wilkes University's NSG 533 Advanced Pharmacology course (Exam 4) offers
a rigorous compilation of 150 practice questions and answers, designed to assess and reinforce mastery of
advanced pharmacotherapeutic principles. The content spans critical areas such as antimicrobial stewardship,
cardiovascular pharmacotherapy, psychopharmacology, and pain management, with a focus on clinical
decision-making and patient-centered care. Each question is accompanied by a detailed rationale that explains the
correct answer and distracts, facilitating deep understanding of drug mechanisms, interactions, and adverse
effects. The material is updated to reflect the latest guidelines and pharmacological advances, ensuring relevance
for the 2026-2027 academic year. This resource is indispensable for graduate nursing students aiming to achieve a
high level of competency in advanced pharmacology and excel in their examinations.
Keywords:
Advanced Pharmacology, NSG 533, Wilkes University, Exam 4, Practice Questions, Pharmacotherapeutics,
Nursing Education, 2026-2027
Answer Format:
Each question is presented in a multiple-choice format with four options, followed by the correct answer and a
comprehensive rationale. The rationale explains the underlying pharmacological principles, clinical reasoning, and
evidence-based guidelines, while also addressing common misconceptions. Distractor explanations are provided to
clarify why incorrect options are not the best choices, enhancing the learning experience.
Page 1
,Compliance Checklist:
Aligned with the 2026-2027 Wilkes University NSG 533 course syllabus
Incorporates the latest FDA-approved drug information and black box warnings
References current clinical practice guidelines (e.g., AHA, IDSA, APA)
Includes rationales that meet advanced practice nursing educational standards
Verified for accuracy by subject matter experts in pharmacology
Content Area Overview:
Content Area Questions Key Topics Weight
Antimicrobial Therapy 1-30 Antibiotics, antivirals, antifungals, 20%
resistance mechanisms, stewardship
Cardiovascular Pharmacology 31-60 Antihypertensives, antiarrhythmics, heart 20%
failure medications, anticoagulants,
antiplatelets
Psychopharmacology 61-90 Antidepressants, antipsychotics, anxiolytics, 20%
mood stabilizers, stimulants
Pain Management and Analgesia 91-110 Opioids, NSAIDs, adjuvant analgesics, 13%
opioid stewardship, acute/chronic pain
Endocrine and Metabolic Agents 111-130 Insulin, oral hypoglycemics, thyroid 13%
medications, corticosteroids, osteoporosis
drugs
Special Populations and 131-150 Pediatric dosing, geriatric considerations, 14%
Pharmacogenomics pregnancy/lactation, pharmacogenomic
testing, renal/hepatic adjustments
Page 2
,Q1. A patient on long-term warfarin therapy requires an antifungal. Which azole is
most likely to cause a clinically significant drug interaction, and what is the primary
mechanism?
A. Fluconazole: CYP2C9 inhibition leading to increased warfarin levels
B. Ketoconazole: CYP3A4 inhibition leading to decreased warfarin levels
C. Micafungin: CYP2C19 induction leading to decreased warfarin levels
D. Terbinafine: CYP2D6 inhibition leading to increased warfarin levels
Correct Answer: A. Fluconazole: CYP2C9 inhibition leading to increased warfarin
levels
Rationale: Fluconazole is a potent inhibitor of CYP2C9, the major enzyme responsible for
metabolizing the more active S-warfarin enantiomer, thereby increasing warfarin's
anticoagulant effect and bleeding risk. Ketoconazole primarily inhibits CYP3A4, which
has a minor role in warfarin metabolism, and its impact on warfarin is less pronounced.
Micafungin does not significantly affect CYP enzymes, and terbinafine inhibits CYP2D6,
which is not involved in warfarin metabolism.
Why Wrong:
B - Ketoconazole's CYP3A4 inhibition affects warfarin less, and it does not decrease
warfarin levels.
C - Micafungin is not a significant CYP inhibitor or inducer.
D - Terbinafine inhibits CYP2D6, not the primary pathway for warfarin.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34
Q2. In a patient with type 2 diabetes and chronic kidney disease (eGFR 25
mL/min/1.73m²), which medication is most appropriate for glycemic control without
requiring dose adjustment?
A. Metformin
B. Sitagliptin
C. Liraglutide
D. Glyburide
Correct Answer: C. Liraglutide
Rationale: Liraglutide, a GLP-1 receptor agonist, is safe to use in severe renal
impairment (eGFR <30) without dose adjustment, as its clearance is not significantly
affected by renal function. Metformin is contraindicated when eGFR <30 due to lactic
acidosis risk. Sitagliptin requires dose reduction in moderate-to-severe renal impairment.
Glyburide has active metabolites that accumulate in renal failure, increasing
hypoglycemia risk.
Why Wrong:
A - Metformin is contraindicated at eGFR <30 due to lactic acidosis risk.
B - Sitagliptin requires dose adjustment for eGFR <45.
Page 3
, D - Glyburide accumulates in renal failure, increasing hypoglycemia risk.
Reference: American Diabetes Association. (2024). Standards of Care in Diabetes-2024.
Diabetes Care, 47(Suppl 1), S179-S187.
Q3. Which pharmacodynamic principle best explains why a drug with a high
therapeutic index is generally safer than one with a low therapeutic index?
A. The margin between the minimum effective concentration and the toxic
concentration is wide.
B. The drug has a shorter half-life, allowing rapid elimination if toxicity occurs.
C. The drug exhibits zero-order kinetics, leading to predictable plasma levels.
D. The drug's efficacy is independent of receptor occupancy.
Correct Answer: A. The margin between the minimum effective concentration and
the toxic concentration is wide.
Rationale: The therapeutic index (TI) is the ratio of the median toxic dose to the median
effective dose (TD50/ED50). A high TI indicates a wide margin between therapeutic and
toxic concentrations, meaning the drug can be administered at effective doses with a low
risk of toxicity. A short half-life does not necessarily confer safety. Zero-order kinetics can
cause unpredictable levels. Efficacy independent of receptor occupancy is not related to
safety margin.
Why Wrong:
B - Half-life affects dosing frequency, not the safety margin between efficacy and
toxicity.
C - Zero-order kinetics can increase toxicity risk due to non-linear accumulation.
D - The TI is about the margin between therapeutic and toxic doses, not receptor
occupancy.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 3
Q4. A patient with heart failure with reduced ejection fraction (HFrEF) is started on
sacubitril/valsartan. Which monitoring parameter is most critical during the first
weeks of therapy?
A. Serum potassium and renal function
B. Blood glucose levels
C. Liver function tests
D. Complete blood count
Correct Answer: A. Serum potassium and renal function
Rationale: Sacubitril/valsartan, an ARNI, can cause hyperkalemia and worsening renal
function, especially in patients with pre-existing renal impairment or those taking other
RAAS inhibitors. Monitoring potassium and creatinine is essential to prevent adverse
outcomes. Blood glucose, liver function, and CBC are not the primary monitoring
Page 4
Document | 2026/2027 Edition | 150 Verified Questions - 115
Questions with Answers
Wilkes NSG 533 Advanced Pharmacology Exam 4 2026-115 QUESTIONS AND ANSWERS ALREADY GRADED
A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation resource for Wilkes University's NSG 533 Advanced
Pharmacology course (Exam 4) contains 150 verified practice questions and answers, meticulously
aligned with the 2026-2027 academic year's curriculum and the latest clinical practice guidelines. Each
question is designed to test advanced pharmacotherapeutic concepts, including drug mechanisms,
adverse effects, drug interactions, and patient-specific considerations. The document serves as an
essential tool for graduate nursing students seeking to excel in their pharmacology coursework and
prepare for board examinations.
Key Features:
Pharmacokinetics and pharmacodynamics of major drug classes
Clinical application of antimicrobial, cardiovascular, and psychotropic agents
Evidence-based prescribing for special populations (geriatric, pediatric, pregnant)
Drug-drug interactions and adverse effect management
Patient education and monitoring parameters for high-alert medications
Case-based scenarios to enhance critical thinking and clinical reasoning
Updates for 2026:
- Updated to reflect the latest FDA approvals and safety alerts as of 2026
- Revised to incorporate current evidence-based guidelines from major medical societies
- Expanded rationales to include recent clinical trial findings and pharmacogenomic considerations
- Enhanced coverage of opioid stewardship and controlled substance prescribing regulations
- Aligned with the 2026-2027 AACN Essentials and advanced pharmacology competencies
Abstract:
This exam preparation document for Wilkes University's NSG 533 Advanced Pharmacology course (Exam 4) offers
a rigorous compilation of 150 practice questions and answers, designed to assess and reinforce mastery of
advanced pharmacotherapeutic principles. The content spans critical areas such as antimicrobial stewardship,
cardiovascular pharmacotherapy, psychopharmacology, and pain management, with a focus on clinical
decision-making and patient-centered care. Each question is accompanied by a detailed rationale that explains the
correct answer and distracts, facilitating deep understanding of drug mechanisms, interactions, and adverse
effects. The material is updated to reflect the latest guidelines and pharmacological advances, ensuring relevance
for the 2026-2027 academic year. This resource is indispensable for graduate nursing students aiming to achieve a
high level of competency in advanced pharmacology and excel in their examinations.
Keywords:
Advanced Pharmacology, NSG 533, Wilkes University, Exam 4, Practice Questions, Pharmacotherapeutics,
Nursing Education, 2026-2027
Answer Format:
Each question is presented in a multiple-choice format with four options, followed by the correct answer and a
comprehensive rationale. The rationale explains the underlying pharmacological principles, clinical reasoning, and
evidence-based guidelines, while also addressing common misconceptions. Distractor explanations are provided to
clarify why incorrect options are not the best choices, enhancing the learning experience.
Page 1
,Compliance Checklist:
Aligned with the 2026-2027 Wilkes University NSG 533 course syllabus
Incorporates the latest FDA-approved drug information and black box warnings
References current clinical practice guidelines (e.g., AHA, IDSA, APA)
Includes rationales that meet advanced practice nursing educational standards
Verified for accuracy by subject matter experts in pharmacology
Content Area Overview:
Content Area Questions Key Topics Weight
Antimicrobial Therapy 1-30 Antibiotics, antivirals, antifungals, 20%
resistance mechanisms, stewardship
Cardiovascular Pharmacology 31-60 Antihypertensives, antiarrhythmics, heart 20%
failure medications, anticoagulants,
antiplatelets
Psychopharmacology 61-90 Antidepressants, antipsychotics, anxiolytics, 20%
mood stabilizers, stimulants
Pain Management and Analgesia 91-110 Opioids, NSAIDs, adjuvant analgesics, 13%
opioid stewardship, acute/chronic pain
Endocrine and Metabolic Agents 111-130 Insulin, oral hypoglycemics, thyroid 13%
medications, corticosteroids, osteoporosis
drugs
Special Populations and 131-150 Pediatric dosing, geriatric considerations, 14%
Pharmacogenomics pregnancy/lactation, pharmacogenomic
testing, renal/hepatic adjustments
Page 2
,Q1. A patient on long-term warfarin therapy requires an antifungal. Which azole is
most likely to cause a clinically significant drug interaction, and what is the primary
mechanism?
A. Fluconazole: CYP2C9 inhibition leading to increased warfarin levels
B. Ketoconazole: CYP3A4 inhibition leading to decreased warfarin levels
C. Micafungin: CYP2C19 induction leading to decreased warfarin levels
D. Terbinafine: CYP2D6 inhibition leading to increased warfarin levels
Correct Answer: A. Fluconazole: CYP2C9 inhibition leading to increased warfarin
levels
Rationale: Fluconazole is a potent inhibitor of CYP2C9, the major enzyme responsible for
metabolizing the more active S-warfarin enantiomer, thereby increasing warfarin's
anticoagulant effect and bleeding risk. Ketoconazole primarily inhibits CYP3A4, which
has a minor role in warfarin metabolism, and its impact on warfarin is less pronounced.
Micafungin does not significantly affect CYP enzymes, and terbinafine inhibits CYP2D6,
which is not involved in warfarin metabolism.
Why Wrong:
B - Ketoconazole's CYP3A4 inhibition affects warfarin less, and it does not decrease
warfarin levels.
C - Micafungin is not a significant CYP inhibitor or inducer.
D - Terbinafine inhibits CYP2D6, not the primary pathway for warfarin.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34
Q2. In a patient with type 2 diabetes and chronic kidney disease (eGFR 25
mL/min/1.73m²), which medication is most appropriate for glycemic control without
requiring dose adjustment?
A. Metformin
B. Sitagliptin
C. Liraglutide
D. Glyburide
Correct Answer: C. Liraglutide
Rationale: Liraglutide, a GLP-1 receptor agonist, is safe to use in severe renal
impairment (eGFR <30) without dose adjustment, as its clearance is not significantly
affected by renal function. Metformin is contraindicated when eGFR <30 due to lactic
acidosis risk. Sitagliptin requires dose reduction in moderate-to-severe renal impairment.
Glyburide has active metabolites that accumulate in renal failure, increasing
hypoglycemia risk.
Why Wrong:
A - Metformin is contraindicated at eGFR <30 due to lactic acidosis risk.
B - Sitagliptin requires dose adjustment for eGFR <45.
Page 3
, D - Glyburide accumulates in renal failure, increasing hypoglycemia risk.
Reference: American Diabetes Association. (2024). Standards of Care in Diabetes-2024.
Diabetes Care, 47(Suppl 1), S179-S187.
Q3. Which pharmacodynamic principle best explains why a drug with a high
therapeutic index is generally safer than one with a low therapeutic index?
A. The margin between the minimum effective concentration and the toxic
concentration is wide.
B. The drug has a shorter half-life, allowing rapid elimination if toxicity occurs.
C. The drug exhibits zero-order kinetics, leading to predictable plasma levels.
D. The drug's efficacy is independent of receptor occupancy.
Correct Answer: A. The margin between the minimum effective concentration and
the toxic concentration is wide.
Rationale: The therapeutic index (TI) is the ratio of the median toxic dose to the median
effective dose (TD50/ED50). A high TI indicates a wide margin between therapeutic and
toxic concentrations, meaning the drug can be administered at effective doses with a low
risk of toxicity. A short half-life does not necessarily confer safety. Zero-order kinetics can
cause unpredictable levels. Efficacy independent of receptor occupancy is not related to
safety margin.
Why Wrong:
B - Half-life affects dosing frequency, not the safety margin between efficacy and
toxicity.
C - Zero-order kinetics can increase toxicity risk due to non-linear accumulation.
D - The TI is about the margin between therapeutic and toxic doses, not receptor
occupancy.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 3
Q4. A patient with heart failure with reduced ejection fraction (HFrEF) is started on
sacubitril/valsartan. Which monitoring parameter is most critical during the first
weeks of therapy?
A. Serum potassium and renal function
B. Blood glucose levels
C. Liver function tests
D. Complete blood count
Correct Answer: A. Serum potassium and renal function
Rationale: Sacubitril/valsartan, an ARNI, can cause hyperkalemia and worsening renal
function, especially in patients with pre-existing renal impairment or those taking other
RAAS inhibitors. Monitoring potassium and creatinine is essential to prevent adverse
outcomes. Blood glucose, liver function, and CBC are not the primary monitoring
Page 4
